-+ 0.00%
-+ 0.00%
-+ 0.00%

PASITHEA THERAPEUTICS ANNOUNCES GRANT OF RARE PEDIATRIC DISEASE DESIGNATION (RPDD) BY FDA TO PAS-004 FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1)

Reuters·04/20/2026 11:01:00

Please log in to view news